Clinical Trials

Blogs

Managing the Screen Failure Rate in NASH Clinical Trials: The Use of Cytokeratin 18 Assays as a Prescreening Tool
Clinical Trial News

Are Clinical Trials Really That Costly? These Researchers Say They Don’t Have to Be

Are You Spending Too Much on Risk-Based Monitoring?

Interventional vs. Non-Interventional: Considerations for Correctly Classifying Your Clinical Study

Renal Trials in the Asia Pacific: Where Are We & What Does the Future Hold?

Sponsor-Facilitated Relationships Between Late Stage Researchers and Phase 1 Sites: A Novel Model for Early Phase Studies

Demystifying IRT Terminology

Biomarkers in NASH Drug Development: Using Cytokeratin 18 as a Secondary Endpoint in Clinical Trials

Getting the Most Out of Interactive Response Technology in Clinical Trial Supply

Patient Recruitment Strategies: New Methods for Scale-Up and Eliminating Redundancies

Digital Health: Optimizing Clinical Trials with Patient-Centric Technology

Using the PACT-Q to Assess Patients’ Anticoagulant Treatment Experience in Clinical Research

eCOA Translations and Cultural Adaptation: Best Practices and Efficiencies

Past, Present and Future of eSource and its Effect on Data Management and Clinical Sites
Clinical Trial News

Why FDA’s Breakthrough Therapy Designation May Be Giving Unproven Drugs an Unfair Advantage